search
Back to results

Mannitol Challenge Test in Adult Asthma Patients With Fixed Dose Combinations

Primary Purpose

Asthma

Status
Completed
Phase
Phase 4
Locations
Sweden
Study Type
Interventional
Intervention
Mannitol challenge test & reversibility test
Sponsored by
Mundipharma AB
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Asthma focused on measuring Asthma, mannitol challenge test, Sweden, primary care

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria

  1. Males and females, age 18-65 years.
  2. Subjects diagnosed with asthma.
  3. Subjects with a baseline FEV1 of ≥70% of the predicted value.
  4. Outpatients at primary clinic.
  5. Subjects treated with a fixed dose combination for at least the last three months.
  6. Subjects who have withheld their asthma- and allergy medication according to individual instructions at the day of the challenge test.
  7. Subjects who are able to read and comprehend Swedish and are willing to sign an informed consent.

Exclusion Criteria

  1. Subjects with evidence of any other respiratory and/or obstructive disease including recent infection/exacerbation.
  2. Subjects treated with a oral corticosteroid within 4 weeks (28 days) prior to the day of the challenge test.
  3. Any history of hypersensitivity to mannitol challenge test.
  4. Any contraindications to use of the diagnostic study medication.
  5. Subjects who are unsuitable for other reason(s) in the opinion of the investigator.

Sites / Locations

  • Näsets Läkargrupp i Höllviken

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Inhaler

Arm Description

Subjects prescribed fixed dose combinations perform Mannitol Challenge Test and Reversibility Test once

Outcomes

Primary Outcome Measures

Mannitol challenge test (Aridol™) + short-acting β2-agonist - positive response.
For the Primary efficacy variable, positive response Mannitol challenge test (Aridol™) followed by short-acting β2-agonist will be given as number and percentage for the ITT-population, as defined by the following: ≥15% fall in FEV1 from baseline; 10% incremental fall in FEV1 between two consecutive doses in the test; Reversibility test with a short-acting β2-agonist - increase in FEV1 of ≥15% from the last dose of mannitol in the challenge test.

Secondary Outcome Measures

Full Information

First Posted
September 8, 2011
Last Updated
August 8, 2012
Sponsor
Mundipharma AB
search

1. Study Identification

Unique Protocol Identification Number
NCT01449123
Brief Title
Mannitol Challenge Test in Adult Asthma Patients With Fixed Dose Combinations
Official Title
An Open-label Single Site Single Dose Pilot Study Using Mannitol Challenge Test With the Purpose to Explore Treatment With Fixed Dose Combinations in Adult Subjects With Asthma in Primary Care in Sweden
Study Type
Interventional

2. Study Status

Record Verification Date
August 2012
Overall Recruitment Status
Completed
Study Start Date
September 2011 (undefined)
Primary Completion Date
April 2012 (Actual)
Study Completion Date
April 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Mundipharma AB

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The primary objective in this pilot study is to explore if asthma patients prescribed fixed dose combinations (budenosid/formoterol (Symbicort®), salmeterol/fluticasone (Seretide®), beclometasone/formoterol (Innovair®) are optimal treated regarding the mannitol challenge test and the following reversibility test. The primary endpoint is to identify asthma patients responding positive or negative to the mannitol challenge test and/or the reversibility test. The hypothesis is that not all patients are well treated.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma
Keywords
Asthma, mannitol challenge test, Sweden, primary care

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
97 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Inhaler
Arm Type
Experimental
Arm Description
Subjects prescribed fixed dose combinations perform Mannitol Challenge Test and Reversibility Test once
Intervention Type
Drug
Intervention Name(s)
Mannitol challenge test & reversibility test
Intervention Description
Patients perform an asthma control test (ACT) to establish if they are "well controlled" or "symptomatic". All patients will perform then perform the mannitol challenge test. Aridol™ is an indirect osmotic bronchial challenge test which can be used to identify bronchial hyperresponsiveness
Primary Outcome Measure Information:
Title
Mannitol challenge test (Aridol™) + short-acting β2-agonist - positive response.
Description
For the Primary efficacy variable, positive response Mannitol challenge test (Aridol™) followed by short-acting β2-agonist will be given as number and percentage for the ITT-population, as defined by the following: ≥15% fall in FEV1 from baseline; 10% incremental fall in FEV1 between two consecutive doses in the test; Reversibility test with a short-acting β2-agonist - increase in FEV1 of ≥15% from the last dose of mannitol in the challenge test.
Time Frame
One day only (Day 1). Subjects complete an ACT, the mannitol challenge test and the reversibility test. This is the end of the study, there is no follow up.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria Males and females, age 18-65 years. Subjects diagnosed with asthma. Subjects with a baseline FEV1 of ≥70% of the predicted value. Outpatients at primary clinic. Subjects treated with a fixed dose combination for at least the last three months. Subjects who have withheld their asthma- and allergy medication according to individual instructions at the day of the challenge test. Subjects who are able to read and comprehend Swedish and are willing to sign an informed consent. Exclusion Criteria Subjects with evidence of any other respiratory and/or obstructive disease including recent infection/exacerbation. Subjects treated with a oral corticosteroid within 4 weeks (28 days) prior to the day of the challenge test. Any history of hypersensitivity to mannitol challenge test. Any contraindications to use of the diagnostic study medication. Subjects who are unsuitable for other reason(s) in the opinion of the investigator.
Facility Information:
Facility Name
Näsets Läkargrupp i Höllviken
City
Höllviken
Country
Sweden

12. IPD Sharing Statement

Learn more about this trial

Mannitol Challenge Test in Adult Asthma Patients With Fixed Dose Combinations

We'll reach out to this number within 24 hrs